EMvision Medical Devices Ltd
ASX:EMV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EMvision Medical Devices Ltd
Cash & Cash Equivalents
EMvision Medical Devices Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash & Cash Equivalents
AU$17.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Cash & Cash Equivalents
AU$18m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cash & Cash Equivalents
AU$6.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
29%
|
CAGR 10-Years
0%
|
|
|
Cochlear Ltd
ASX:COH
|
Cash & Cash Equivalents
AU$187.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
9%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash & Cash Equivalents
AU$17.7m
|
CAGR 3-Years
79%
|
CAGR 5-Years
14%
|
CAGR 10-Years
34%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Cash & Cash Equivalents
AU$15.2m
|
CAGR 3-Years
30%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
EMvision Medical Devices Ltd
Glance View
EMvision Medical Devices Ltd. engages in the development & commercialization of medical imaging technology. The company is headquartered in Brisbane, Queensland. The company went IPO on 2018-12-13. The Company’s principal activity consists of research and development of medical imaging and diagnostic technology for the purpose of commercializing portable medical device for stroke diagnosis and monitoring, as well as other medical imaging needs. The firm is engaged in developing portable brain scanner for stroke diagnosis and monitoring.
See Also
What is EMvision Medical Devices Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
17.5m
AUD
Based on the financial report for Dec 31, 2025, EMvision Medical Devices Ltd's Cash & Cash Equivalents amounts to 17.5m AUD.
What is EMvision Medical Devices Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
6%
Over the last year, the Cash & Cash Equivalents growth was 29%. The average annual Cash & Cash Equivalents growth rates for EMvision Medical Devices Ltd have been 22% over the past three years , 6% over the past five years .
